8-K: Catheter Precision Reports 74% Revenue Increase in Q1 2025, Acquires Cardionomics Assets

Catheter Precision, Inc. announces a 74% increase in sales revenue for Q1 2025 and the acquisition of Cardionomics, Inc.'s assets.

Summary

• Catheter Precision, Inc. (VTAK) reported its financial results and operational update for the quarter ending March 31, 2025.
• Sales revenues for the quarter increased by 74% to approximately $143 thousand, compared to $82 thousand in the same quarter of the previous year.
• The company's net loss for the quarter was approximately $4.0 million, including approximately $1.2 million in non-cash charges.
• As of March 31, 2025, total assets were $24.8 million and total shareholders' equity was $7.9 million.
• The company's cash position as of March 31, 2025, was $450 thousand.
• Subsequent to the end of the quarter, on May 12th, the Company announced a $1.5 million gross proceeds investment from institutional investors via a private placement of its securities.
• The company acquired the assets of Cardionomics, Inc., including a Cardiac Pulmonary Nerve Stimulation System for treating acute decompensated heart failure (ADHF), along with 49 issued patents and 46 patent applications.
• Approximately 50 hospitals are evaluating VIVO and LockeT devices.
• The company received notice of allowance from the US Patent Office for its first U.S. patent for the LockeT device.
• The company participated in several medical conferences, including the Heart Rhythm Society symposium, presenting clinical data on VIVO and LockeT.
• Additional clinical studies of VIVO and LockeT are ongoing or planned for 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the significant revenue growth and strategic acquisition, but tempered by the net loss, low cash position, and the need for additional financing.

Positives

• The company experienced a significant increase in sales revenue, growing by 74% compared to the same quarter last year.
• The acquisition of Cardionomics' assets provides the company with a new therapy for ADHF and a substantial patent portfolio.
• Clinical data presented at major conferences supports the efficacy and safety of VIVO and LockeT, leading to increased interest and sales leads.
• The company secured a $1.5 million investment, providing additional capital.
• Multiple IRB approvals were received for new LockeT studies, including direct comparisons to competitive devices.

Negatives

• The company reported a net loss of approximately $4.0 million for the quarter, although this includes $1.2 million in non-cash charges.
• The company's cash position is relatively low at $450 thousand as of March 31, 2025.
• The company acknowledges that it will take 9-12 months to see the clinical acceptance of new products in the hospital to create sales growth due to the committee evaluation requirements.

Risks

• The company states that it does not have sufficient liquidity to fund operations unless it obtains additional financing or enters into a strategic transaction within the next three to six months.
• The company's future success depends on the acceptance of its products by hospitals, physicians, and patients.
• The company operates in a highly competitive industry and faces risks related to regulatory requirements, potential product recalls, and changes in trade policies.
• The company acknowledges that its internal controls and disclosure controls were not effective as of December 31, 2024 and March 31, 2025, which could impact its ability to accurately report financial results.

Future Outlook

The company is optimistic about the growth of its product pipeline and is committed to continued research and engagement with new and existing customers. Additional clinical studies of both VIVO and LockeT are either currently ongoing or planned for 2025 which are intended to further demonstrate efficacy and improved workflows.

Management Comments

• David Jenkins, CEO of Catheter Precision, commented, 'We continue to be optimistic about the growth of the product pipeline.'
• He also noted that it would take 9-12 months to see clinical acceptance of new products and create sales growth due to committee evaluation requirements.
• The company is committed to continued research supporting the product benefits and increasing the engagement of new and existing customers.

Industry Context

Catheter Precision operates in the competitive medical device industry, specifically focusing on electrophysiology products. The company's participation in major conferences like the Heart Rhythm Society and American College of Cardiology highlights its efforts to engage with key opinion leaders and promote its products. The acquisition of Cardionomics' assets expands the company's portfolio into the treatment of acute decompensated heart failure, potentially opening new market opportunities.

Comparison to Industry Standards

• It is difficult to compare Catheter Precision directly to industry giants like Medtronic or Boston Scientific due to its smaller size and focus on niche electrophysiology products.
• However, the 74% revenue increase suggests strong growth potential compared to the more modest growth rates typically seen in larger, more established medical device companies.
• The clinical data presented on VIVO and LockeT at major conferences aims to establish the company's products as competitive alternatives to standard of care methods, such as manual compression for hemostasis.
• The company's focus on non-invasive 3D imaging with VIVO aligns with the industry trend towards less invasive and more precise diagnostic and therapeutic approaches.

Stakeholder Impact

• Shareholders may be impacted by the company's need for additional financing and its ability to achieve profitability.
• Employees are affected by the company's growth prospects and its ability to secure funding for operations.
• Customers (physicians and hospitals) benefit from the company's innovative products and clinical data supporting their efficacy.
• Suppliers are impacted by the company's ability to obtain components and manage its supply chain.
• Creditors are exposed to risks related to the company's liquidity and its ability to meet its financial obligations.

Next Steps

• Continue ongoing and planned clinical studies of VIVO and LockeT.
• Pursue additional financing or strategic transactions to address liquidity concerns.
• Focus on product expansion and growth goals to achieve profitability.
• Continue to engage with new and existing customers to drive sales growth.
• Begin Randomized Controlled Trial (RCT) is planned for VIVO in Q3 2025.

Key Dates

Keywords

Catheter Precision, VTAK, electrophysiology, VIVO, LockeT, Cardionomics, cardiac arrhythmias, medical device, financial results, clinical studies